Search results for "immunoglobulin"

showing 10 items of 841 documents

Inducible Co-Stimulator Null MRL-Fas lpr Mice

2005

MRL/MpJ-Tnfrsf6lpr (MRL-Faslpr) mice develop a spontaneous T cell-dependent autoimmune disease that shares features with human lupus, including fatal nephritis, systemic pathology, and autoantibodies (autoAb). The inducible co-stimulator (ICOS) is upregulated on activated T cells and modulates T cell-mediated responses. To investigate whether ICOS has an essential role in regulating autoimmune lupus nephritis and the systemic illness in MRL-Faslpr mice, ICOS null (-/-) MRL Faslpr and ICOS intact (+/+) MRL-Faslpr strains (wild-type [WT]) were generated and compared. It was determined that in ICOS-/- MRL-Faslpr as compared with the WT strain, (1) there is a significant reduction in circulatin…

Antigens Differentiation T-LymphocyteMice Inbred MRL lprT-LymphocytesT cellLupus nephritismedicine.disease_causeBlood Urea NitrogenAutoimmunityInducible T-Cell Co-Stimulator ProteinInterferon-gammaMiceImmune systemimmune system diseasesmedicineAnimalsskin and connective tissue diseasesAutoantibodiesMice Inbred C3HSystemic lupus erythematosusTumor Necrosis Factor-alphabusiness.industryAutoantibodyGeneral Medicinemedicine.diseaseLupus NephritisIsotypeInterleukin-10Mice Inbred C57BLProteinuriamedicine.anatomical_structureNephrologyImmunoglobulin GImmunologyInterleukin-4businessNephritisJournal of the American Society of Nephrology
researchProduct

Acetylcholine via Muscarinic Receptors Inhibits Histamine Release from Human Isolated Bronchi

1997

Human bronchi were incubated in organ baths to measure histamine release. The calcium ionophore A23187 (10 mumol/L; 1 min) stimulated histamine release by 148 +/- 28% (n = 11) above the prestimulation level but was ineffective in epithelium-denuded bronchi. Neither bradykinin (0.1 mumol/L) nor compound 48/80 (10 micrograms/ml) triggered the release of histamine from epithelium-intact bronchi. Acetylcholine did not affect spontaneous histamine release (about 2 nmol/g x 5 min) but inhibited A23187-evoked histamine release in an atropine-sensitive manner. Already a concentration as low as 0.1 nmol/L acetylcholine was effective, the maximal inhibition (by 89%) occurred at 100 nmol/L, whereas a …

AtropinePulmonary and Respiratory MedicineAgonistPhysostigminemedicine.medical_specialtyTime Factorsmedicine.drug_classPhysostigmineBradykininBronchiMuscarinic AntagonistsMuscarinic AgonistsCritical Care and Intensive Care MedicineHistamine Releasechemistry.chemical_compoundCulture TechniquesInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansDrug InteractionsCalcimycinDose-Response Relationship DrugIonophoresbusiness.industryOxotremorineImmunoglobulin EReceptors MuscarinicAcetylcholineEndocrinologychemistryAcetylcholinesterase inhibitorDepression ChemicalCholinesterase InhibitorsbusinessAcetylcholineHistaminemedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Mechanisms of resistance to autoimmune disease induced by T-cell vaccination.

1991

Many human autoimmune diseases tend to progress slowly. Phases of rapid progression may come to a halt and may be followed by transient or even permanent remissions. Autoimmune diseases in animals either arise spontaneously or are induced. The former tend to be slowly progressive, the latter mostly acute to subacute, and usually followed by spontaneous remissions. The mechanisms at work that prevent rapid disease progression and can effect remissions are poorly understood, but they may provide us with a clue both to natural self-tolerance and to the therapeutic induction of self-tolerance.

Autoimmune diseaseEncephalomyelitis Autoimmune Experimentalbusiness.industrymedicine.medical_treatmentEncephalomyelitisT-LymphocytesImmunologyExperimental autoimmune encephalomyelitisT-cell vaccinationImmunization PassiveImmunotherapymedicine.diseaseImmune toleranceAutoimmune DiseasesVaccinationImmunoglobulin IdiotypesImmunopathologyImmunologymedicineImmune ToleranceImmunology and AllergyAnimalsbusinessAutoimmunity
researchProduct

Protein Corona: Prevention of Dominant IgG Adsorption on Nanocarriers in IgG‐Enriched Blood Plasma by Clusterin Precoating (Adv. Sci. 10/2019)

2019

The development of nanocarriers for drug delivery is challenged by individual blood composition fluctuations. In article number 1802199, Svenja Morsbach and co‐workers report the accumulation of immunoglobulins in the protein corona of nanocarriers in IgG‐enriched blood plasma resulting in increased cell uptake. This could be prevented by pre‐coating the nanocarriers with the “stealth” protein clusterin. Cover design by Stefan Schuhmacher.

Back Coverstealth effectnanocarriersClusterinbiologyclusterinChemistryGeneral Chemical EngineeringGeneral EngineeringGeneral Physics and AstronomyMedicine (miscellaneous)Protein CoronaBiochemistry Genetics and Molecular Biology (miscellaneous)Molecular biologyImmunoglobulin Gimmunoglobulin Gprotein coronaAdsorptionBlood plasmabiology.proteinGeneral Materials ScienceNanocarriersAdvanced Science
researchProduct

PEG-benzofulvene copolymer hydrogels for antibody delivery.

2010

A new amphiphilic copolymer have been synthesized starting from the hydrosoluble polyaspartylhydrazide (PAHy) polymer, by grafting both hydrophilic PEG(2000) chains and hydrophobic palmitic acid (C(16)) moieties on polymer backbone, and the structure of obtained PAHy-PEG(2000)-C(16) copolymer have been characterized by 2D (1)H/(13)C NMR experiments. PAHy-PEG(2000)-C(16) copolymer showed the ability of self-assembling in aqueous media giving a core-shell structure and resulted potentially useful for encapsulating and dissolving hydrophobic drug. The formation of micellar core-shell structure has been investigated by 2D (1)H NMR NOESY experiments. The presence of cross-peaks for protons of C(…

BiocompatibilityCell SurvivalPolymersSurface PropertiesPEG-benzofulvene immunoglobulin delivery hydrogelsimmunoglobulinsPharmaceutical SciencePolyethylene Glycolschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorPolymer chemistryPEG ratioCopolymerHumansantibody deliverybenzofulvene copolymerschemistry.chemical_classificationChemistrytechnology industry and agricultureHydrogelsantibody delivery; benzofulvene copolymers; hydrogels; immunoglobulinsPolymerMacromonomerIndenesSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoImmunoglobulin GDrug deliverySelf-healing hydrogelsbenzofulvene copolymerhydrogelDrug Screening Assays AntitumorRheologyEthylene glycolInternational journal of pharmaceutics
researchProduct

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

2017

International audience; Improved bifunctional chelating agents (BFC) are required for copper-64 radiolabelling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific imaging agents. Four different bifunctional chelating agents (BFC) were evaluated for Fab (Fragment antigen binding) conjugation and radiolabelling with copper-64. Two DOTA- (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and two NOTA- (1,4,7-triazacyclononane-1,4,7-triacetic acid) derivatives bearing a p-benzyl-isothiocyanate group were conjugated to Fab-trastuzumab - which targets the HER2/neu receptor - and the average number of chelators attached ranged from 2.4 to 4.3 macrocycles …

BiodistributionImmunoconjugatesmedicine.drug_class[SDV.CAN]Life Sciences [q-bio]/CancerMonoclonal antibody030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/CancerInorganic ChemistryHeterocyclic Compounds 1-RingImmunoglobulin Fab FragmentsMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineAnimalsHumansDOTA[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyTissue DistributionChelationBifunctionalChelating AgentsRadiochemistryMammary Neoplasms ExperimentalTrastuzumabIn vitroImmunoconjugateCopper RadioisotopesBiochemistrychemistryPositron-Emission Tomography030220 oncology & carcinogenesis[SDV.IMM]Life Sciences [q-bio]/ImmunologyCopper-64
researchProduct

Giant liposomes as model membranes for immunological studies: spontaneous insertion of purified K1-antigen (poly-alpha-2,8-NeuAc) of Escherichia coli.

1990

A flow chamber has been constructed to use giant liposomes (diameter 5-50 microns) as model membranes for immunological studies and other experiments involving the interaction with water-soluble compounds. As an example of immunological importance, the insertion of purified K-antigen from Escherichia coli K1 has been studied. Despite its large hydrophilic part (poly-alpha-2,8-NeuAc), which is capped at its potential reducing end with phosphatidic acid acting as a lipid anchor group, this water-soluble material is readily incorporated into liposomal membranes of dimyristoylphosphatidylcholine (DMPC). The incorporation has been proven by immunofluorescence using a FITC-labeled monoclonal anti…

BiophysicsFluorescent Antibody TechniqueNeuraminidaseBiologymedicine.disease_causeBiochemistryModels BiologicalResidue (chemistry)chemistry.chemical_compoundMembrane LipidsmedicineEscherichia coliMicroscopy Phase-ContrastEscherichia coliHEPESchemistry.chemical_classificationLiposomeAntigens BacterialAntibodies MonoclonalWaterCell BiologyPhosphatidic acidbiology.organism_classificationEnterobacteriaceaeEnzymeMembranechemistryBiochemistrySolubilityImmunoglobulin GAntigens SurfaceLiposomesDimyristoylphosphatidylcholineBiochimica et biophysica acta
researchProduct

Biosensor Analysis of β2-Glycoprotein I–Reactive Autoantibodies: Evidence for Isotype-Specific Binding and Differentiation of Pathogenic from Infecti…

2007

Abstract Background: For the laboratory diagnosis of the antiphospholipid syndrome (APS) we developed a biosensor with the ability to distinguish between disease-relevant anti-β2-glycoprotein I (β2GPI) autoantibodies (anti-β2GPI) and pathogen-specific β2GPI cross-reactive antibodies that occur transiently during infections. Methods: We used a surface plasmon resonance (SPR) biosensor device. For the detection of anti-β2GPI in serum samples, affinity-purified human β2GPI was covalently attached to a functionalized n-alkanethiol self-assembling monolayer on the biosensor chip. After verifying the specificity of the biosensor system with a panel of monoclonal antibodies to β2GPI, we analyzed s…

Biosensor devicemedicine.drug_classClinical BiochemistryEnzyme-Linked Immunosorbent AssayBiosensing TechniquesCross Reactionsmedicine.disease_causeMonoclonal antibodyAutoimmunityParvoviridae InfectionsAntiphospholipid syndromeParvovirus B19 HumanmedicineHumansLupus Erythematosus SystemicSyphilisTreponema pallidumAntigens ViralAutoantibodiesAntigens BacterialbiologyParvovirusBiochemistry (medical)AutoantibodySurface Plasmon ResonanceAntiphospholipid Syndromemedicine.diseasebiology.organism_classificationIsotypeMolecular biologyImmunoglobulin Isotypesbeta 2-Glycoprotein IImmunologyAntibodies Antiphospholipidbiology.proteinAntibodyProtein BindingClinical Chemistry
researchProduct

Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci

2006

No vaccine is available for preventing infections by serogroup B Neisseria meningitidis (MenB), which accounts for a major portion of meningococcal cases in developed countries, because of the poor immunogenicity of the capsular polysaccharide (CP) even after protein conjugation. We have previously induced anticapsular antibodies by immunization with a single chain variable fragment (scFv), which mimics a protective CP epitope. This surrogate antigen, however, was ineffective at inducing serum bactericidal activity, an accepted marker of protection in humans. Serum bactericidal activity was consistently achieved by immunizing mice with the scFv-encoding gene. Immunization with vectors witho…

Blood Bactericidal ActivityImmunologyImmunoglobulin Variable Regionchemical and pharmacologic phenomenaBlood Bactericidal ActivityNeisseria meningitidis Serogroup BEpitopeArticleMicrobiologyDNA vaccinationMiceAntigenserogroup B Neisseria meningitidis; single chain variable fragment; DNA vaccinationChlorocebus aethiopsVaccines DNAImmunology and AllergyAnimalsRats WistarMice Inbred BALB CbiologyImmunogenicityArticlesVirologyAntibodies BacterialRatsBacterial vaccineMeningococcal InfectionsImmunizationAnimals NewbornBacterial VaccinesCOS Cellsbiology.proteinAntibody
researchProduct

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct